About Cathay Biotech
Cathay Biotech is a publicly listed company based in Shanghai (China) founded in 1997. It operates as a producer of industrial biotechnology polymers and solvents. Cathay Biotech has raised $213 million across 3 funding rounds from investors including Goldman Sachs, HBM Healthcare Investments and Lu'an Chemical Group. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio and 5 more; 8 of its 10 listed competitors have raised funding.
Company details
Cathay Biotech was founded in 1997 in Shanghai, China, within the industrial biotechnology sector. Polymers and solvents are manufactured, with a product portfolio that includes dibasic acids, 5-diamine, and Terryl for textiles. Custom manufacturing of polymers is provided, alongside services for process design in fermentation and bio-production operations.
- Headquarters Shanghai, China
- SectorsHealthcare
- Website cathaybiotech.com
- Social LinkedIn X
- Legal Name Cathay Biotech, Inc. Class A
- Annual Revenue$469.93 M (USD)11.5as on Dec 31, 2025
- Net Profit$80.09 M (USD)14.68as on Dec 31, 2025
- EBITDA$114.28 M (USD)18.37as on Dec 31, 2025
- Total Equity Funding$213M (USD)
in 3 rounds
- Latest Funding Round$135M (USD), Private Equity Round
Dec 2015
- InvestorsGoldman Sachs
& 2 more
Funding Insights of Cathay Biotech
Cathay Biotech has successfully raised a total of $213M across 3 strategic funding rounds. The most recent funding activity was a Private Equity Round of $135 million completed in December 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $213M
- Total Rounds 3
- Last Round Private Equity Round — $135M
- First Round $26M
(May 2006)
- Investors Count 3
All 3 funding rounds of Cathay Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2015 | $135M | Private Equity Round | – | – | |
| Dec 2006 | $52M | Series B | – | – | |
| May 2006 | $26M | Series A | – | – | – |
3 investors in total: 3 institutional.
Investors in Cathay Biotech
Cathay Biotech has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Goldman Sachs, HBM Healthcare Investments and Lu'an Chemical Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment banking services are delivered across multiple financial sectors. | 1869 | goldmansachs.com | New York, United States | |
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
- | – | chinaluan.com | - |
Investor details for Cathay Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cathay Biotech
5 people are tracked at Cathay Biotech (3 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Xiucai Liu | CEO | Leadership |
Howard Chou | VP, R&D | Leadership |
宇鎏 杜 | Deputy Director of R&D | Leadership |
Tony Liu | Engineering Manager | Team |
Lipeng Sun | Sales manager | Team |
Complete people profiles for Cathay Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Cathay Biotech
Cathay Biotech is a publicly listed company on the SSE with ticker symbol 688065 in China, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Aug 2020
- Listed onSSE: 688065
- Listed entityCathay Biotech, Inc. Class A
- Exchange sectorProcess industries
- ISINCNE100004447
- Share price36.65 CNY (-2.27% on the day) · 2026-10-14
- Market capitalisation27,048,367,753.00 CNY
- Price to earnings42.2
- EPS (diluted, trailing year)0.87 CNY
- Dividend yield1.2%
- Volume (last session)3,266,706
Financials of Cathay Biotech
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 3.29B CNY | 560.7M CNY | 800.1M CNY |
| 2024 | 2.95B CNY | 489.0M CNY | 675.9M CNY |
| 2023 | 2.11B CNY | 366.5M CNY | 440.3M CNY |
| 2022 | 2.43B CNY | 553.3M CNY | 650.4M CNY |
| 2021 | 2.36B CNY | 594.7M CNY | 673.2M CNY |
Detailed financial statements for Cathay Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Cathay Biotech
4 dated milestones of Cathay Biotech across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Cathay Biotech is founded.
- Funding First funding round of $26.0M.
- Funding Latest funding round, Private Equity Round, of $135.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Cathay Biotech
Cathay Biotech has 10 listed competitors in our database, 8 of them funded. They include Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed competitors of Cathay Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cathay Biotech
Websites that share an audience with Cathay Biotech (cathaybiotech.com).
Websites whose visitors overlap most with Cathay Biotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
upchem.com | upchem.com | 100% | – | – | – |
jhjlchem.com | jhjlchem.com | 100% | – | – | – |
| chinadmc.com | 100% | – | – | View details | |
szjhchem.com | szjhchem.com | 100% | – | – | – |
| ethox.com | 100% | 5.1K | #3,495,543 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Cathay Biotech
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Cathay Biotech (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cathay Biotech
Complete news archive for Cathay Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cathay Biotech
Cathay Biotech was founded in 1997 and raised its 1st funding round 9 years after it was founded.
Cathay Biotech is headquartered in Shanghai, China.
Cathay Biotech is a funded company, having raised a total of $213M across 3 funding rounds to date. The company's 1st funding round was a Series A of $26M, raised on May 2006.
Annual revenue of Cathay Biotech is $469.93M as on Dec 31, 2025.
Cathay Biotech was founded in 1997 in Shanghai, China, within the industrial biotechnology sector. Polymers and solvents are manufactured, with a product portfolio that includes dibasic acids, 5-diamine, and Terryl for textiles. Custom manufacturing of polymers is provided, alongside services for process design in fermentation and bio-production operations.
Cathay Biotech's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Yes, Cathay Biotech is publicly traded on SSE under the ticker symbol 688065.
Cathay Biotech has 3 investors. Key investors include Goldman Sachs, HBM Healthcare Investments, and Lu'an Chemical Group.